The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Iukina M.Iu.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

Nuralieva N.F.

Endocrinology Research Centre, Moscow, Russia

Troshina E.A.

Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

Kuznetsov N.S.

Endocrinology Research Centrer

Platonova N.M.

Endocrinology Research Centre, Moscow, Russia

The hypoglicemic syndrome (insulinoma): topical, pathomorphological, and genetic diagnostics and treatment (review, part 2)

Authors:

Iukina M.Iu., Nuralieva N.F., Troshina E.A., Kuznetsov N.S., Platonova N.M.

More about the authors

Journal: Problems of Endocrinology. 2017;63(5): 346‑355

DOI: 10.14341/probl2017635346-355

Views: 3682

Downloaded: 81

Download PDF (RU)
Contact the author
Table of contents

THE HYPOGLICEMIC SYNDROME (INSULINOMA): TOPICAL, PATHOMORPHOLOGICAL, AND GENETIC DIAGNOSTICS AND TREATMENT (REVIEW, PART 2)
THE HYPOGLICEMIC SYNDROME (INSULINOMA): TOPICAL, PATHOMORPHOLOGICAL, AND GENETIC DIAGNOSTICS AND TREATMENT (REVIEW, PART 2)

To cite this article:

Iukina MIu, Nuralieva NF, Troshina EA, Kuznetsov NS, Platonova NM. The hypoglicemic syndrome (insulinoma): topical, pathomorphological, and genetic diagnostics and treatment (review, part 2). Problems of Endocrinology. 2017;63(5):346‑355. (In Russ.)
https://doi.org/10.14341/probl2017635346-355

МСФ на ЯМ
Close metadata
Recommended articles:
Mini­mally inva­sive inte­rventions for complications asso­ciated with intra-abdominal calculi after lapa­roscopic cholecystectomy. Piro­gov Russian Journal of Surgery. 2024;(5):14-20
Use of systemic steroids in hospitalized patients with COVID-19. Russian Journal of Preventive Medi­cine. 2024;(5):75-80
Our expe­rience in the treatment of congenital nasal median hete­rotopias in children and an overview of various treatment tactics. Russian Bulletin of Otorhinolaryngology. 2024;(2):28-32
Clinical and anatomical rationale for the effe­ctiveness of treatment of phle­gmon of the floor of the oral cavity and deep cellular spaces of the neck complicated with sepsis. Russian Journal of Operative Surgery and Clinical Anatomy. 2024;(2):19-25
Chro­nic rhinosinusitis with nasal polyps as the first stage in the deve­lopment of eosi­nophilic granulomatosis with polya­ngiitis. Russian Rhinology. 2024;(2):157-166
B vita­mins and diseases of the peri­pheral nervous system. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5):75-82
Asthenia in young patients and possibilities for its correction. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5):133-137
Expe­rience with the use of risdiplam in a fami­lial case of spinal muscular atro­phy 5q in patients with a homo­zygous dele­tion of the SMN1 gene and the same copy number of the SMN2 gene. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5):138-141
Arti­ficial inte­lligence in dermatology: oppo­rtunities and prospects. Russian Journal of Clinical Dermatology and Vene­reology. 2024;(3):246-252
Sleep diso­rders during pregnancy. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5-2):99-104

Insulinoma is the most common functioning tumor of the pancreas. It consists of β-cells of the Langerhans islets. Insulinoma is malignant in 10% of cases and multifocal in 10% of cases. This review discusses the new capabilities for identification of the exact location of insulinoma, in particular given the latest data on expression of different receptors in the tumor tissue. We discuss the modern concept of molecular and genetic aspects of insulinoma development. In particular, we analyze studies on germinal and somatic mutations and epigenetic abnormalities. We describe new biochemical markers of insulinoma, which may be used for differential diagnosis, timely detection of insulinoma recurrence and progression, individual prognosis, and monitoring of treatment. Also, we discuss application of antitumor medications and optimal drug correction of hypoglycemia in insulinoma patients.

Keywords:

insulinoma
pancreas
diagnosis
receptor anomalies
biochemical markers
genetic disorders
treatment
insulinoma
pancreas
diagnosis
receptor anomalies
biochemical markers
genetic disorders
treatment
insulinoma
pancreas
diagnosis
receptor anomalies
biochemical markers
genetic disorders
treatment
insulinoma
pancreas
diagnosis
receptor anomalies
biochemical markers
genetic disorders
treatment
insulinoma
pancreas
diagnosis
receptor anomalies
biochemical markers
genetic disorders
treatment

Authors:

Iukina M.Iu.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

Nuralieva N.F.

Endocrinology Research Centre, Moscow, Russia

Troshina E.A.

Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

Kuznetsov N.S.

Endocrinology Research Centrer

Platonova N.M.

Endocrinology Research Centre, Moscow, Russia

List of references:

  1. McAuley G, Delaney H, Colville J, et al. Multimodality preoperative imaging of pancreatic insulinomas. Clin Radiol. 2005;60(10):1039-1050. doi:10.1016/j.crad.2005.06.005
  2. Beltsevich DG. ENETS consensus guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system. Endocrine Surgery. 2012;6(3):8-40. (In Russ.)
  3. Cryer PE, Axelrod L, Grossman AB, et al. Evaluation and management of adult hypoglycemic disorders: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2009;94(3):709-728. doi:10.1210/jc.2008-1410
  4. An L, Li W, Yao KC, et al. Assessment of contrast-enhanced ultrasonography in diagnosis and preoperative localization of insulinoma. Eur J Radiol. 2011;80(3):675-680. doi:10.1016/j.ejrad.2010.09.014
  5. Taieb D, Legmann P, Prat F, et al. Topographic diagnosis: respective roles of morphological and functional imaging. Ann Endocrinol (Paris). 2013;74(3):185-190. doi:10.1016/j.ando.2013.05.008
  6. D’Onofrio M, Mansueto G, Vasori S, et al. Contrast-enhanced ultrasonographic detection of small pancreatic insulinoma. J Ultrasound Med. 2003;22(4):413-417.
  7. Rebours V, Cordova J, Couvelard A, et al. Can pancreatic neuroendocrine tumour biopsy accurately determine pathological characteristics? Dig Liver Dis. 2015;47(11):973-977. doi:10.1016/j.dld.2015.06.005
  8. Starkov IG, Solodinina EN, Egorov AV, et al. Endoscopic ultrasonography in the diagnosis of neuroendocrine tumors of the pancreas.Eksperimental’naya i Klinicheskaya Gastroenterologiya. 2010;(10):37-45. (In Russ.)
  9. Ishikawa T, Itoh A, Kawashima H, et al. Usefulness of EUS combined with contrast-enhancement in the differential diagnosis of malignant versus benign and preoperative localization of pancreatic endocrine tumors. Gastrointest Endosc. 2010;71(6):951-959. doi:10.1016/j.gie.2009.12.023
  10. Lin XZ, Wu ZY, Tao R, et al. Dual energy spectral CT imaging of insulinoma-Value in preoperative diagnosis compared with conventional multi-detector CT. Eur J Radiol. 2012;81(10):2487-2494. doi:10.1016/j.ejrad.2011.10.028
  11. Won JGS, Tseng H-S, Yang A-H, et al. Intra-arterial calcium stimulation test for detection of insulinomas: detection rate, responses of pancreatic peptides, and its relationship to differentiation of tumor cells. Metabolism. 2003;52(10):1320-1329. doi:10.1016/s0026-0495(03)00200-2
  12. Desimone ME, Weinstock RS. Non-Diabetic Hypoglycemia. [Updated 2016 Mar 25]. In: De Groot LJ, Chrousos G, Dungan K, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc. 2000—2016. Available from: https://www.ncbi.nlm.nih.gov/books/NBK355894/
  13. Ambrosini V, Nanni C, Fanti S. The use of gallium-68 labeled somatostatin receptors in PET/CT imaging. PET Clinics. 2014;9(3):323-329. doi:10.1016/j.cpet.2014.03.008
  14. Wild D, Christ E, Caplin ME, et al. Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas. J Nucl Med. 2011;52(7):1073-1078. doi:10.2967/jnumed.110.085142
  15. Christ E, Wild D, Ederer S, et al. Glucagon-like peptide-1 receptor imaging for the localisation of insulinomas: a prospective multicentre imaging study. Lancet Diabet Endocrinol. 2013;1(2):115-122. doi:10.1016/s2213-8587(13)70049-4
  16. Antwi K, Fani M, Heye T, et al. Localisation of insulinoma: comparison of glucagon-like peptide-1 receptor (GLP1-R) SPECT/CT, PET/CT and MRI. Preliminary results of a prospective clinical study. J Nucl Med. 2015;56(supplement 3):144-144.
  17. Iglesias P, Lafuente C, Martín Almendra MÁ, et al. Insulinoma: a multicenter, retrospective analysis of three decades of experience (1983—2014). Endocrinología y Nutrición (English Edition). 2015;62(7):306-313. doi:10.1016/j.endoen.2015.08.006
  18. Gama R. Best practice No 173: clinical and laboratory investigation of adult spontaneous hypoglycaemia. J Clin Pathol. 2003;56(9):641-646. doi:10.1136/jcp.56.9.641
  19. Carrère N, Mathonnet M, Mirallié É, et al. Surgical treatment. Ann Endocrinol (Paris). 2013;74(3):191-195. doi:10.1016/j.ando.2013.05.004
  20. Carneiro DM, Levi JU, Irvin GL, 3rd. Rapid insulin assay for intraoperative confirmation of complete resection of insulinomas. Surgery. 2002;132(6):937-942; discussion 942-933. doi:10.1067/msy.2002.128481
  21. Tabarin A, Goichot B, French Endocrine S. Treatment: symptomatic treatment of hypoglycaemia. Ann Endocrinol (Paris). 2013;74(3):196-199. doi:10.1016/j.ando.2013.05.009
  22. Nakamura A, Mitsuhashi T, Takano Y, et al. Usefulness of the octreotide test in Japanese patients for predicting the presence/absence of somatostatin receptor 2 expression in insulinomas. Endocr J. 2016;63(2):135-142. doi:10.1507/endocrj.EJ15-0371
  23. Gullo D, Evans JL, Sortino G, et al. Insulin autoimmune syndrome (Hirata Disease) in European Caucasians taking alpha-lipoic acid. Clin Endocrinol (Oxf). 2014;81(2):204-209. doi:10.1111/cen.12334
  24. Okabayashi T, Shima Y, Sumiyoshi T, et al. Diagnosis and management of insulinoma. World J Gastroenterol. 2013;19(6):829-837. doi:10.3748/wjg.v19.i6.829
  25. Quinn TJ, Yuan Z, Adem A, et al. Pasireotide (SOM230) is effective for the treatment of pancreatic neuroendocrine tumors (PNETs) in a multiple endocrine neoplasia type 1 (MEN1) conditional knockout mouse model. Surgery. 2012;152(6):1068-1077. doi:10.1016/j.surg.2012.08.021
  26. Tirosh A, Stemmer SM, Solomonov E, et al. Pasireotide for malignant insulinoma. Hormones (Athens). 2016;15(2):271-276. doi:10.14310/horm.2002.1639
  27. Ramage JK, Davies AH, Ardill J, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut. 2005;54 Suppl 4:iv1-iv16. doi:10.1136/gut.2004.053314
  28. Scoazec JY, Couvelard A, Leteurtre E, et al. Pathology. Ann Endocrinol (Paris). 2013;74(3):203-206. doi:10.1016/j.ando.2013.05.005
  29. Díaz Pérez JÁ, Currás Freixes M. Chromogranin A and neuroendocrine tumors. Endocrinología y Nutrición (English Edition). 2013;60(7):386-395. doi:10.1016/j.endoen.2012.10.007
  30. Qiao X-W, Qiu L, Chen Y-J, et al. Chromogranin A is a reliable serum diagnostic biomarker for pancreatic neuroendocrine tumors but not for insulinomas. BMC Endocr Disord. 2014;14(1). doi:10.1186/1472-6823-14-64
  31. Ramachandran R, Bech P, Murphy KG, et al. Comparison of the utility of cocaine- and amphetamine-regulated transcript (CART), chromogranin A, and chromogranin B in neuroendocrine tumor diagnosis and assessment of disease progression. J Clin Endocr Metab. 2015;100(4):1520-1528. doi:10.1210/jc.2014-3640
  32. Tomita T. PGP 9.5 immunocytochemical staining for pancreatic endocrine tumors. Islets. 2014;5(3):122-128. doi:10.4161/isl.25351
  33. Jakobsen AM, Ahlman H, Kölby L, et al. NESP55, a novel chromogranin-like peptide, is expressed in endocrine tumours of the pancreas and adrenal medulla but not in ileal carcinoids. Br J Cancer. 2003;88(11):1746-1754. doi:10.1038/sj.bjc.6600924
  34. Raffel A, Eisenberger CF, Cupisti K, et al. Increased EpCAM expression in malignant insulinoma: potential clinical implications. Eur J Endocrinol. 2010;162(2):391-398. doi:10.1530/eje-08-0916
  35. Krug S, Kuhnemuth B, Griesmann H, et al. CUX1: a modulator of tumour aggressiveness in pancreatic neuroendocrine neoplasms. Endocrine Related Cancer. 2014;21(6):879-890. doi:10.1530/erc-14-0152
  36. Alkatout I, Friemel J, Sitek B, et al. Novel prognostic markers revealed by a proteomic approach separating benign from malignant insulinomas. Mod Pathol. 2014;28(1):69-79. doi:10.1038/modpathol.2014.82
  37. Minnetti M, Grossman A. Somatic and germline mutations in NETs: Implications for their diagnosis and management. Best Pract Res Clin Endocrinol Metab. 2016;30(1):115-127. doi:10.1016/j.beem.2015.09.007
  38. Gillam MP, Nimbalkar D, Sun L, et al. MEN1 tumorigenesis in the pituitary and pancreatic islet requires Cdk4 but not Cdk2. Oncogene. 2015;34(7):932-938. doi:10.1038/onc.2014.3
  39. Hamze Z, Vercherat C, Bernigaud-Lacheretz A, et al. Altered MENIN expression disrupts the MAFA differentiation pathway in insulinoma. Endocr Relat Cancer. 2013;20(6):833-848. doi:10.1530/ERC-13-0164
  40. Karpathakis A, Dibra H, Thirlwell C. Neuroendocrine tumours: cracking the epigenetic code. Endocr Relat Cancer. 2013;20(3):R65-R82. doi:10.1530/ERC-12-0338
  41. Dejeux E, Olaso R, Dousset B, et al. Hypermethylation of the IGF2 differentially methylated region 2 is a specific event in insulinomas leading to loss-of-imprinting and overexpression. Endocr Relat Cancer. 2009;16(3):939-952. doi:10.1677/ERC-08-0331
  42. Duerr EM, Chung DC. Molecular genetics of neuroendocrine tumors. Best Pract Res Clin Endocrinol Metab. 2007;21(1):1-14. doi:10.1016/j.beem.2006.12.001
  43. Cromer MK, Choi M, Nelson-Williams C, et al. Neomorphic effects of recurrent somatic mutations in Yin Yang 1 in insulin-producing adenomas. Proc Natl Acad Sci USA. 2015;112(13):4062-4067. doi:10.1073/pnas.1503696112
  44. Masjkur J, Arps-Forker C, Poser SW, et al. Hes3 is expressed in the adult pancreatic islet and regulates gene expression, cell growth, and insulin release. J Biol Chem. 2014;289(51):35503-35516. doi:10.1074/jbc.M114.590687
  45. Liu SH, Rao DD, Nemunaitis J, et al. PDX-1 is a therapeutic target for pancreatic cancer, insulinoma and islet neoplasia using a novel RNA interference platform. PLoS One. 2012;7(8):e40452. doi:10.1371/journal.pone.0040452
  46. Desai SS, Modali SD, Parekh VI, et al. GSK-3beta protein phosphorylates and stabilizes HLXB9 protein in insulinoma cells to form a targetable mechanism of controlling insulinoma cell proliferation. J Biol Chem. 2014;289(9):5386-5398. doi:10.1074/jbc.M113.533612
  47. Cheung SS, Ou D, Metzger DL, et al. B7-H4 expression in normal and diseased human islet beta cells. Pancreas. 2014;43(1):128-134. doi:10.1097/MPA.0b013e31829695d2
  48. Metukuri MR, Zhang P, Basantani MK, et al. ChREBP mediates glucose-stimulated pancreatic beta-cell proliferation. Diabetes. 2012;61(8):2004-2015. doi:10.2337/db11-0802
  49. Zhao F, Huang F, Tang M, et al. Nodal induces apoptosis through activation of the ALK7 signaling pathway in pancreatic INS-1 beta-cells. Am J Physiol Endocrinol Metab. 2012;303(1):E132-E143. doi:10.1152/ajpendo.00074.2012
  50. Kim HS, Han TY, Yoo YM. Melatonin-Mediated Intracellular Insulin during 2-deoxy-d-glucose treatment is reduced through autophagy and EDC3 protein in insulinoma INS-1E cells. Oxid Med Cell Longev. 2016;2016:2594703. doi:10.1155/2016/2594703
  51. Reubi JC, Waser B. Triple-peptide receptor targeting in vitro allows detection of all tested gut and bronchial NETs. J Nucl Med. 2015;56(4):613-615. doi:10.2967/jnumed.114.153189
  52. Tomita T, Masuzaki H, Noguchi M, et al. GPR40 gene expression in human pancreas and insulinoma. Biochem Biophys Res Commun. 2005;338(4):1788-1790. doi:10.1016/j.bbrc.2005.10.161
  53. Odori S, Hosoda K, Tomita T, et al. GPR119 expression in normal human tissues and islet cell tumors: evidence for its islet-gastrointestinal distribution, expression in pancreatic beta and alpha cells, and involvement in islet function. Metabolism. 2013;62(1):70-78. doi:10.1016/j.metabol.2012.06.010
  54. Li C-J, Zhou H-L, Li J, et al. Roles of sulfonylurea receptor 1 and multidrug resistance protein 1 in modulating insulin secretion in human insulinoma. Hepatobiliary Pancreat Dis Int. 2011;10(1):88-94. doi:10.1016/s1499-3872(11)60013-1

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.